[{"address1": "2222 Ponce de Leon Boulevard", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786 629 1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sergio  Traversa M.B.A., Pharm.D.", "age": 63, "title": "CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 719041, "exercisedValue": 0, "unexercisedValue": 34490}, {"maxAge": 1, "name": "Mr. Maged S. Shenouda M.B.A., R.Ph.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 450353, "exercisedValue": 0, "unexercisedValue": 25070}, {"maxAge": 1, "name": "Mr. Charles S. Ence CPA, M.B.A.", "age": 58, "title": "Chief Accounting & Compliance Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 568679, "exercisedValue": 0, "unexercisedValue": 2203}, {"maxAge": 1, "name": "Dr. Paolo  Manfredi M.D., Ph.D.", "age": 61, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gina  DiGuglielmo", "title": "VP & Head of Clinical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marco  Pappagallo M.D.", "age": 64, "title": "Chief Clinical Officer", "yearBorn": 1959, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Hixon", "title": "Head of Commercial", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard M. Mangano", "age": 73, "title": "Consultant", "yearBorn": 1950, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1709078400, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.125, "open": 6.2, "dayLow": 6.12, "dayHigh": 6.87, "regularMarketPreviousClose": 6.125, "regularMarketOpen": 6.2, "regularMarketDayLow": 6.12, "regularMarketDayHigh": 6.87, "beta": 0.098, "forwardPE": -2.5757575, "volume": 512054, "regularMarketVolume": 512054, "averageVolume": 323196, "averageVolume10days": 196170, "averageDailyVolume10Day": 196170, "bid": 6.63, "ask": 7.5, "bidSize": 900, "askSize": 1400, "marketCap": 204674560, "fiftyTwoWeekLow": 2.0, "fiftyTwoWeekHigh": 6.87, "fiftyDayAverage": 4.263, "twoHundredDayAverage": 3.2497, "currency": "USD", "enterpriseValue": 98407480, "floatShares": 25537067, "sharesOutstanding": 30099200, "sharesShort": 1734662, "sharesShortPriorMonth": 1564373, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.057600003, "heldPercentInsiders": 0.07819, "heldPercentInstitutions": 0.4638, "shortRatio": 6.83, "shortPercentOfFloat": 0.0586, "impliedSharesOutstanding": 30099200, "bookValue": 3.346, "priceToBook": 2.0322773, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -111570952, "trailingEps": -3.71, "forwardEps": -2.64, "lastSplitFactor": "1:4", "lastSplitDate": 1569801600, "52WeekChange": 0.78571427, "SandP52WeekChange": 0.25882936, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RLMD", "underlyingSymbol": "RLMD", "shortName": "Relmada Therapeutics, Inc.", "longName": "Relmada Therapeutics, Inc.", "firstTradeDateEpochUtc": 1403271000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f101bc4b-2b97-3da3-a498-9e630b405138", "messageBoardId": "finmb_9070579", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.8, "targetHighPrice": 25.0, "targetLowPrice": 3.0, "targetMeanPrice": 10.38, "targetMedianPrice": 6.75, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 106267104, "totalCashPerShare": 3.531, "quickRatio": 12.617, "currentRatio": 12.954, "returnOnAssets": -0.48763, "returnOnEquity": -0.83551, "freeCashflow": -38926968, "operatingCashflow": -77292392, "financialCurrency": "USD", "trailingPegRatio": null}]